'Superficial' bladder cancer - Time to uncouple pT1 tumours from pTa tumours

BJU International

Volumn 90, Issue 9, 2002, Pages 846-852

  Bryan, R T ^a   Wallace, D M A ^a,b  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b QUEEN ELIZABETH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; MITOMYCIN C; MOLECULAR MARKER; THIOTEPA; TUMOR MARKER;

BLADDER CANCER; CANCER INVASION; CANCER STAGING; CHROMOSOME ABERRATION; CYSTOSCOPY; HUMAN; PRIORITY JOURNAL; REVIEW; SUPERFICIAL CANCER; TRANSURETHRAL RESECTION; BLADDER TUMOR; DISEASE COURSE; MORTALITY; NOMENCLATURE; PATHOLOGY; PROGNOSIS; TRANSITIONAL CELL CARCINOMA;

CARCINOMA, TRANSITIONAL CELL; DISEASE PROGRESSION; HUMANS; NEOPLASM STAGING; PROGNOSIS; TERMINOLOGY; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS;

EID: 0036884336     PISSN: 14644096     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1464-410X.2002.03053.x     Document Type: Review

References (65)

1. Sobin LH, Wittekind C eds. UICC TNM Atlas, 5th edn. New York: John Wiley & Sons, Inc, 1997
2. McFarlane JP, Ellis BW, Harland SJ. The management of superficial bladder cancer: an interactive seminar. Br J Urol 1996; 78: 372-8
3. Wallace DMA, Bryan RT, Dunn JA, Begum G, Bathers S. Delay and survival in bladder cancer. BJU Int 2002; 89: 868-78
4. Malmström PU, Busch C, Norlen BJ. Recurrence, progression and survival in bladder cancer. Scand J Urol Nephrol 1987; 21: 185-95
5. Sternberg CN, Pansadoro V, Calabro F et al. Neo-adjuvant chemotherapy and bladder preservation in locally advanced transitional cell carcinoma of the bladder. Ann Oncol 1999; 10: 1301-5
6. Lutzeyer W, Rübben H, Dahm H. Prognostic parameters in superficial bladder cancer, an analysis of 315 cases. J Urol 1982; 127: 250-2
7. Holmäng S, Hedelin H, Anderström C, Johansson SL. The relationship among multiple recurrences, progression and prognosis of patients with stages Ta and T1 transitional cell cancer of the bladder followed for at least 20 years. J Urol 1995; 153: 1823-6
8. Heney NM, Ahmed S, Flanagan MJ et al. for National Bladder Cancer Collaborative Group A. Superficial bladder cancer, progression and recurrence. J Urol 1983; 130: 1083-6
9. Pocock RD, Ponder BAJ, O'Sullivan JP, Ibrahim SK, Easton DF, Shearer RJ. Prognostic factors in non-infiltrating carcinoma of the bladder: a preliminary report. Br J Urol 1982; 54: 711-5
10. Herr HW, Badalament RA, Amato DA, Laudone VP, Fair WR, Whitmore WF Jr. Superficial bladder cancer treated with bacillus Calmette-Guerin, a multivariate analysis of factors affecting tumor progression. J Urol 1989; 141: 22-9
11. MRC Working Party on Urological Cancer. The effect of intravesical thiotepa on the recurrence rate of newly diagnosed superficial bladder cancer. An MRC study. Br J Urol 1985; 57: 680
12. Tolley DA, Hargreave TB, Smith PH et al. Effect of intravesical mitomycin C on the recurrence of newly diagnosed superficial bladder cancer: interim report from the Medical Research Council Subgroup on Superficial Bladder Cancer (Urological Cancer Working Party). Br Med J 1988; 296: 1759
13. Kiemeney LALM, Witjes JA, Verbeek ALM, Heijbroek RP, Debruyne FMJ and the members of the Dutch South-East Cooperative Urological Group. The clinical epidemiology of superficial bladder cancer. Br J Cancer 1993; 67: 806-12
14. Malmström PU, Wijkström H, Lundholm C et al. and members of the Swedish-Norwegian Bladder Cancer Study Group, 5-year followup of a randomised prospective study comparing mitomycin C and bacillus Calmette-Guerin in patients with superficial bladder carcinoma. J Urol 1999; 161: 1124-7
15. Utz DC. Editorial Comment. J Urol 1983; 130: 1086
16. Catalona WJ. Editorial Comment. J Urol 1989; 141: 28
17. Lamm DL. Editorial Comment. J Urol 1989; 141: 28-9
18. Herr HW. Progression of stage T1 bladder tumors after intravesical bacillus Calmette-Guerin. J Urol 1991; 145: 40-4
19. Parmar MKB, Freedman LS, Hargreave TB, Tolley DA. Prognostic factors for recurrence and followup policies in the treatment of superficial bladder cancer: report from the British Medical Research Council subgroup on superficial bladder cancer (Urological Cancer Working Party). J Urol 1989; 142: 284-8
20. Allard P, Bernard P, Fradet Y, Tetu B. The early clinical course of primary Ta and T1 bladder cancer: a proposed prognostic index. Br J Urol 1998; 81: 692-8
21. Smith G, Elton RA, Chisholm GD, Newsam JE, Hargreave TB. Superficial bladder cancer: intravesical chemotherapy and tumour progression to muscle invasion or metastases. Br J Urol 1986; 58: 659-63
22. Ali-El-Dien B, El-Baz M, Aly ANM, Shamaa S, Ashamallah A. Intravesical epirubicin versus doxorubicin for superficial bladder tumors (stages pTa and pT1): a randomized prospective study. J Urol 1997; 158: 68-74
23. Özen HA, AkdaşA, Alkibay T, Altuì U, Remzi D. Prognostic factors in superficial bladder cancer. Int Urol Nephrol 1986; 18: 417-20
24. Stein JP, Grossfield GD, Ginsberg DA et al. Prognostic markers in bladder cancer, a contemporary review of the literature. J Urol 1998; 160: 645-59
25. Takeichi M. Cadherin cell adhesion receptors as a morphogenetic regulator. Science 1991; 251: 1451-5
26. Gallin WJ, Edelman GM, Cunningham BA. Characterization of L-CAM, a major cell adhesion molecule from embryonic liver cells. Proc Natl Acad Sci USA 1983; 80: 1038-42
27. Birchmeier W, Behrens J. Cadherin expression in carcinomas, role in the formation of cell junctions and the prevention of invasiveness. Biochem Biophys Acta 1994; 1198: 11-26
28. Frixen UH, Behrens J, Sachs M et al. E-cadherin-mediated cell-cell adhesion prevents invasiveness of human carcinoma cells. J Cell Biol 1991; 113: 173-85
29. Vleminckx K, Vakaet L Jr, Mareel M, Fiers W, van Roy F. Genetic manipulation of E-cadherin expression by epithelial tumor cells reveals an invasion suppressor role. Cell 1991; 66: 107-19
30. Jankowski JA, Bruton R, Shepherd N, Sanders DSA. Cadherin and catenin biology represent a global mechanism for epithelial cancer progression. J Clin Pathol: Mol Pathol 1997; 50: 289-90
31. Bringuier PP, Umbas R, Schaafsma HE, Karthaus HF, Debruyne FM, Schalken JA. Decreased E-cadherin immunoreactivity correlates with poor survival in patients with bladder tumours. Cancer Res 1993; 53: 3241-5
32. Syrigos KN, Krausz T, Waxman J et al. E-cadherin expression in bladder cancer using formalin-fixed, paraffin-embedded tissues, correlation with histopathological grade, tumour stage and survival. Int J Cancer 1995; 64: 367-70
33. Garcia del Muro X, Torregrosa A, Munz J et al. Prognostic value of the expression of E-cadherin and α-catenin in bladder cancer. Eur J Urol 2000; 36: 357-62
34. Popov Z, Gil-Diez de Medina S, Lefrere-Belda M-A et al. Low E-cadherin expression in bladder cancer at the transcriptional and protein level provides prognostic information. Br J Cancer 2000; 83: 209-14
35. Bryan RT, Hardy RG, Yeo Y et al. Increased P-cadherin expression identifies a more invasive phenotype of bladder transitional cell carcinoma. BJU Int 2002; 90 (Suppl. 1): 39
36. Lane DP. Cancer. p53, guardian of the genome. Nature 1992; 358: 15-6
37. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science 1991; 253: 49-53
38. Sarkis AS, Dalbagni G, Cordon-Cardo C et al. Nuclear overexpression of p53 protein in transitional cell bladder carcinomas: a marker for disease progression. JNCI 1993; 85: 53-9
39. Esrig D, Spruck CH III, Nichols PW et al. p53 nuclear protein accumulation correlates with mutations in the p53 gene, tumor grade, and stage in bladder cancer. Am J Pathol 1993; 143: 1389-97
40. Nouri AME, Darakhshan F, Cannell H, Paris AMI, Oliver RTD. The relevance of p53 mutations in urological malignancies: possible implications for bladder cancer. Br J Urol 1996; 78: 337-44
41. Shiina H, Igawa M, Shigeno K et al. Clinical significance of mdm2 and p53 expression in bladder cancer. A comparison with cell proliferation and apoptosis. Oncology 1999; 56: 239-47
42. Reiher F, Ozer O, Pins M, Jovanovic BD, Eggener S, Campbell SC. p53 and microvessel density in primary resection specimens of superficial bladder cancer. J Urol 2002; 167: 1469-74
43. Spruck CH III, Ohneseit PF, Gonzalez-Zulueta M et al. Two molecular pathways to transitional cell carcinoma of the bladder. Cancer Res 1994; 54: 784-8
44. Moch H, Sauter G, Moore D, Mihatsch MJ, Gudat F, Waldman F. p 53 and erbB-2 protein overexpression are associated with early invasion and metastasis in bladder cancer. Virchows Arch Pathol Anat Histopathol 1993; 423: 329-34
45. Gerdes J, Schwab U, Lemke H, Stein H. Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int J Cancer 1983; 31: 13-20
46. Okamura K, Miyake K, Koshikawa T, Asai J. Growth fractions of transitional cell carcinomas of the bladder defined by the monoclonal antibody Ki-67. J Urol 1990; 144: 875-8
47. Tsujihashi H, Nakanishi A, Matsuda H, Uejima S, Kurita T. Cell proliferation of human bladder tumours determined by BrdUrd and Ki-67 immunostaining. J Urol 1991; 145: 846-9
48. Bush C, Price P, Norten J et al. Proliferation in human bladder carcinoma measured by Ki-67 antibody labelling: its potential clinical importance. Br J Cancer 1991; 64: 357-60
49. Fontana D, Bellina M, Gubetta L et al. Monoclonal antibody Ki-67 in the study of the proliferative activity of bladder carcinoma. J Urol 1992; 148: 1149-51
50. Mulder AH, van Hootegem JC, Sylvester R et al. Prognostic factors in bladder carcinoma, histologic parameters and expression of a cell cycle-related nuclear antigen (Ki-67). J Pathol 1992; 166: 37-43
51. Cohen MB, Waldman FM, Carroll PR, Kerschmann R, Chew K, Mayall BH. Comparison of five histopathologic methods to assess cellular proliferation in transitional cell carcinoma of the urinary bladder. Hum Path 1993 1999; 24: 772-8
52. WAF1/CIP1 and Ki-67 expression in patients with superficial bladder tumors treated with Bacillus Calmette-Guerin intravesical therapy. J Urol 1999; 161: 792-98
53. Wright C, Mellon K, Johnston P et al. Expression of mutant p53, c-erbB-2 and the epidermal growth factor receptor in transitional cell carcinoma of the human urinary bladder. Br J Cancer 1991; 63: 967-70
54. Lipponen P, Eskelinen M. Expression of epidermal growth factor receptor in bladder cancer is related to established prognostic factors, oncoprotein (c-erbB-2, p53) expression and long-term prognosis. Br J Cancer 1994; 69: 1120-5
55. Mellon K, Wright C, Kelly P, Horne CH, Neal DE. Long-term outcome related to epidermal growth factor receptor status in bladder cancer. J Urol 1995; 153: 919-25
56. Neal DE, Smith K, Fennelly JA, Bennett MK, Hall RR, Harris AL. Epidermal growth factor receptor in human bladder cancer, a comparison of immunohistochemistry and ligand binding. J Urol 1989; 141: 517-21
57. Neal DE, Sharples L, Smith K, Fennelly J, Hall RR, Harris AL. The epidermal growth factor receptor and the prognosis of bladder cancer. Cancer 1990; 65: 1619-25
58. Dalbagni G, Presti J, Reuter VE, Fair WR, Cordon-Cardo C. Genetic alterations in bladder cancer. Lancet 1993; 324: 469-71
59. Simoneau AR, Spruck CH III. Gonzalez-Zulueta M et al. Evidence for two tumor suppressor loci associated with proximal chromosome 9p to q and distal chromosome 9q in bladder cancer and the initial screening for GAS1 and PTC mutations. Cancer Res 1996; 56: 5039-43
60. International Statistical Classification of Diseases and Related Health Problems. Tenth Revision ICD-10. Vol. 1. Geneva: World Health Organization, 1992
61. Soloway MS, Sofer M, Vaidya A. Contemporary management of stage T1 transitional cell carcinoma of the bladder. J Urol 2002; 167: 1573-83
62. Hall RR. Application of clinical trials to the care of patients with bladder cancer. Eur Urol 1997; 31 (Suppl. 1): 42-6
63. National Comprehensive Cancer Network Urothelial Cancer Practice Guidelines Panel. NCCN Urothelial Cancer Practice Guidelines, Oncology 1998; 12: 225-71
64. Smith JA Jr, Labasky RF, Cockett ATK, Fracchia JA, Montie JE, Rowland RG. Bladder Cancer Clinical Guidelines Panel summary report on the management of nonmuscle invasive bladder cancer (stages Ta, T1, Tis). J Urol 1999; 162: 1697-701
65. Malmström PU. Management of superficial bladder cancer: what is new? Curr Op Urol 2000; 10: 447-51